FY2022 Earnings Estimate for Repligen Co. Issued By Jefferies Financial Group (NASDAQ:RGEN)

Repligen Co. (NASDAQ:RGENGet Rating) – Equities researchers at Jefferies Financial Group increased their FY2022 EPS estimates for Repligen in a research note issued on Wednesday, August 3rd. Jefferies Financial Group analyst B. Couillard now anticipates that the biotechnology company will earn $3.17 per share for the year, up from their previous forecast of $3.10. The consensus estimate for Repligen’s current full-year earnings is $3.21 per share.

Repligen (NASDAQ:RGENGet Rating) last announced its earnings results on Tuesday, August 2nd. The biotechnology company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.72 by $0.19. The company had revenue of $207.63 million during the quarter, compared to the consensus estimate of $189.06 million. Repligen had a net margin of 20.47% and a return on equity of 11.18%. The firm’s revenue for the quarter was up 27.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.79 earnings per share.

Other analysts also recently issued research reports about the stock. UBS Group assumed coverage on shares of Repligen in a report on Wednesday, July 20th. They issued a “buy” rating and a $213.00 target price for the company. SVB Leerink raised their price objective on shares of Repligen from $220.00 to $250.00 and gave the stock an “outperform” rating in a report on Wednesday. Craig Hallum decreased their price objective on shares of Repligen from $286.00 to $274.00 in a report on Thursday, April 28th. Stephens raised their price objective on shares of Repligen from $220.00 to $275.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, KeyCorp raised their price objective on shares of Repligen from $245.00 to $260.00 and gave the stock an “overweight” rating in a report on Wednesday. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, Repligen presently has a consensus rating of “Moderate Buy” and a consensus price target of $276.00.

Repligen Price Performance

Shares of RGEN stock opened at $246.27 on Friday. The firm has a 50-day moving average of $175.20 and a 200-day moving average of $174.08. The company has a market cap of $13.40 billion, a P/E ratio of 88.91 and a beta of 1.07. Repligen has a one year low of $137.21 and a one year high of $327.32.

Hedge Funds Weigh In On Repligen

Large investors have recently modified their holdings of the company. HM Payson & Co. bought a new position in shares of Repligen in the fourth quarter valued at approximately $26,000. Confluence Wealth Services Inc. bought a new stake in Repligen during the fourth quarter valued at approximately $27,000. Sageworth Trust Co of South Dakota bought a new stake in Repligen during the fourth quarter valued at approximately $46,000. Harding Loevner LP lifted its position in Repligen by 121.3% during the first quarter. Harding Loevner LP now owns 177 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 97 shares during the last quarter. Finally, Rise Advisors LLC bought a new stake in Repligen during the fourth quarter valued at approximately $52,000. 86.82% of the stock is currently owned by institutional investors.

Insider Transactions at Repligen

In other news, insider Christine Gebski sold 3,357 shares of Repligen stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $243.01, for a total value of $815,784.57. Following the completion of the transaction, the insider now owns 30,735 shares in the company, valued at $7,468,912.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Christine Gebski sold 3,357 shares of the firm’s stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $243.01, for a total value of $815,784.57. Following the completion of the transaction, the insider now directly owns 30,735 shares in the company, valued at $7,468,912.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Jon Snodgres sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $220.00, for a total transaction of $440,000.00. Following the completion of the transaction, the chief financial officer now owns 37,187 shares of the company’s stock, valued at $8,181,140. The disclosure for this sale can be found here. Insiders sold 46,874 shares of company stock worth $8,911,739 over the last quarter. Corporate insiders own 1.10% of the company’s stock.

About Repligen

(Get Rating)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

See Also

Earnings History and Estimates for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.